Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to 30.17%.

  • Cytosorbents' EBIT Margin rose 259000.0% to 30.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.11%, marking a year-over-year increase of 258700.0%. This contributed to the annual value of 47.16% for FY2024, which is 556200.0% up from last year.
  • Latest data reveals that Cytosorbents reported EBIT Margin of 30.17% as of Q3 2025, which was up 259000.0% from 37.59% recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' EBIT Margin registered a high of 26.91% during Q1 2021, and its lowest value of 111.17% during Q3 2022.
  • Its 5-year average for EBIT Margin is 64.48%, with a median of 56.08% in 2024.
  • Per our database at Business Quant, Cytosorbents' EBIT Margin crashed by -666500bps in 2021 and then soared by 677900bps in 2024.
  • Over the past 5 years, Cytosorbents' EBIT Margin (Quarter) stood at 88.68% in 2021, then rose by 24bps to 67.69% in 2022, then tumbled by -60bps to 108.54% in 2023, then soared by 62bps to 40.75% in 2024, then grew by 26bps to 30.17% in 2025.
  • Its EBIT Margin stands at 30.17% for Q3 2025, versus 37.59% for Q2 2025 and 44.54% for Q1 2025.